Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Treatment strategies that include induction chemotherapy have several potential advantages:
early initiation of systemic chemotherapy, in vivo assessment of response, and down-staging
of both the primary tumor and regional lymphatic metastases, making breast conservation an
option for many. The aim of the present study is to determine the efficacy and toxicity of
induction combination chemotherapy with the triplet, gemcitabine, epirubicin, and docetaxel,
in patients with locally advanced or inflammatory breast cancer. Clearly, it is in the
upfront treatment as well as in the adjuvant treatment of breast cancer, that effective new
agents and combination of agents are likely to have the greatest potential impact.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Aventis Pharmaceuticals Eli Lilly and Company Pharmacia and Upjohn